Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

Exploring the theranostic role of Lu-177 herceptin in HER2 expressing breast cancer: Preliminary studies on comparison with F-18-FDG PET/CT

Priya Bhusari, JAYA SHUKLA, Devinder Dhawan, Gurpreet Singh and Bhagwant Mittal
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 490;
Priya Bhusari
4Nuclear Medicine Post Graduate Institute of Medical Education and Research Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAYA SHUKLA
3Post Graduate Institute of Medical Education & Res Post Graduate Institute of Medical Education & Res Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devinder Dhawan
2Panjab University Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gurpreet Singh
1Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhagwant Mittal
5Nuclear Medicine & PET Postgraduate Institute of Medical Education & Rese Chandigarh India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

490

Objectives: Herceptin is an anti HER2 antibody and often used for the treatment of HER2 primary and metastatic disease. Lu-177 herceptin may prove as a potential therapeutic option for the metastatic disease. F-18-FDG PET/CT is very useful in evaluating the extent of disease. In this prospective study Lu-177 herceptin was explored for targeting HER2 expressing breast cancer and associated metastatic lesions that were picked up by F-18-FDG PET/CT. Methodology: The radioimmunoconjugate Lu-177-Herceptin was developed in-house in hospital radiopharmacy lab. The preparation was standardized as clinical grade by performing complete quality control and preclinical evaluation. Clinical evaluation was carried out after obtaining clearance from the institute ethics committee and written informed consent from the patients for participation in the study. Patients with biopsy proven breast cancer (n=16; HER2 positive and negative) were administered Lu-177-Herceptin (185-740 MBq). The total protein dose delivered was kept constant (25 mg). All the patients had undergone F-18-FDG PET/CT before undergoing Lu-177-Herceptin study and had at least one F-18-FDG avid lesion. Planar and SPECT/CT imaging was performed on day 5/7 post administration of Lu-177-Herceptin. The images were compared to the F-18-FDG PET/CT images to evaluate the targeting potential of Lu-177-Herceptin for the HER2 lesions. The tumor to background ratio was determined from planar images using region of interest (ROI) analysis. Results: The developed radioimmunoconjugate Lu-177-herceptin had radiochemical purity >95%. The in-house preparations were sterile (on broth incubation) with endotoxin content within permissible limits (<175 EU/V). Lu-177-herceptin imaging showed no localization in all HER2 negative patients (n=4), having F-18-FDG avid lesions. Corresponding to the F-18-FDG uptake localization of Lu-177-Herceptin was observed in primary lesions in 5 out of 11 HER2 positive patients on planar and SPECT/CT images, 1 patient had recurrent lung metastases observed on planar and SPECT/CT images. SPECT/CT, 5 patients had FDG avid metastatic disease. Lu-177-herceptin localization was observed in 3 out of 10 metastatic lesions on whole body image and 8 out of 10 metastatic lesions (including skeletal mets and lymph nodes) on SPECT/CT. Two metastatic lesions were not visualized owing to the low resolution of SPECT/CT. The average maximum tumor to background ratio for primary lesions was 3.9 and for metastatic lesions was 3.2. No non-specific tracer localization was observed. Conclusion: This study concluded that Lu-177-herceptin may hold theranostic potential for use in radioimmunotherapy of HER2 metastatic breast cancer.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exploring the theranostic role of Lu-177 herceptin in HER2 expressing breast cancer: Preliminary studies on comparison with F-18-FDG PET/CT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Exploring the theranostic role of Lu-177 herceptin in HER2 expressing breast cancer: Preliminary studies on comparison with F-18-FDG PET/CT
Priya Bhusari, JAYA SHUKLA, Devinder Dhawan, Gurpreet Singh, Bhagwant Mittal
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 490;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Exploring the theranostic role of Lu-177 herceptin in HER2 expressing breast cancer: Preliminary studies on comparison with F-18-FDG PET/CT
Priya Bhusari, JAYA SHUKLA, Devinder Dhawan, Gurpreet Singh, Bhagwant Mittal
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 490;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Breast Cancer: Novel Tracers, Response Biomarkers, and Therapy

  • FDG-PET/CT versus contrast-enhanced CT for response evaluation in metastatic breast cancer - a systematic review
  • 68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study
Show more Breast Cancer: Novel Tracers, Response Biomarkers, and Therapy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire